-+ 0.00%
-+ 0.00%
-+ 0.00%

Olema to present initial Phase 1 OP-3136 clinical data at ASCO meeting

PUBT·04/21/2026 20:01:48
Listen to the news
Olema to present initial Phase 1 OP-3136 clinical data at ASCO meeting
  • Olema Pharmaceuticals scheduled initial Phase 1 clinical data for OP-3136 to be presented in a poster session at ASCO on May 30, 2026.
  • Disclosure will cover early findings from first-in-human testing of OP-3136 in advanced solid tumors, including use with endocrine therapy in ER+, HER2- advanced breast cancer.
  • Olema also set a trial-in-progress presentation for OPERA-02, a Phase 3 study of palazestrant with ribociclib in first-line ER+, HER2- advanced breast cancer, for June 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211601PRIMZONEFULLFEED9694058) on April 21, 2026, and is solely responsible for the information contained therein.